Skip to main content

MD Anderson Expands BioDiscovery Microarray Software License

NEW YORK (GenomeWeb News) – MD Anderson Cancer Center has expanded its license agreement with bioinformatics company BioDiscovery for the Nexus Copy Number microarray software platform, the company said today.
 
The software is used to analyze and visualize chromosomal aberrations from microarray data, and the agreement allows many users in different labs to use it at the same time. MD Anderson expanded the original site license agreement to enterprise level, BioDiscovery said.
 
The Nexus Copy Number platform supports a variety of microarray platforms including Agilent, Affymetrix, Illumina, GenePix, BlueFuse, ImaGene, Roche NimbleGen, Empire Genomics, and custom data files.
 
Financial terms of the agreement were not released.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.